Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartphone program aims to boost heart function in heart failure patients

NCT ID NCT06947148

Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a comprehensive digital health program for people with heart failure after they leave the hospital. The program included cognitive behavioral therapy, self-monitoring via smartphone, and a special device to track lung fluid. Researchers measured how well patients' hearts recovered over six months, aiming to improve quality of life and reduce readmissions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digital health intervention (cognitive behavioral therapy, self-monitoring, ReDS technology)
What this could lead to
If successful, this could show that a smartphone-based program helps heart failure patients recover better at home and reduces hospital readmissions.
What could go wrong
This is a small, completed study with only 104 participants, so results may not apply to all heart failure patients. The intervention requires smartphone use, which may limit who can benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

104 people

The number who actually took part.

Started

Apr 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients hospitalized for HF, NYHA classification II-IV upon admission 2. The patient's residence is within the urban area of each center, and ReDS™ technology can be performed at home or at the outpatient clinic 3. No difficulty using smartphones, with basic Chinese reading and writing skills 4. Accept the terms and conditions of the study and obtain informed consent from the subjects/their families Exclusion Criteria: 1. Age\<21 years old 2. Patients with height\<155 cm or\>190 cm, BMI\<22 kg/m2 or\>36 kg/m2, chest circumference\<80 cm or\>115 cm, and flail chest or rib fractures 3. History of pulmonary embolism 4. chronic renal failure（Scr \> 443umol/L） 5. History of heart transplantation or pacemaker implantation 6. Severe pulmonary hypertension 7. Suffering from end-stage chronic obstructive pulmonary disease, requiring home oxygen therapy 8. Massive pleural effusion 9. The subject is unable to complete the 6-minute walking test 10. Expected lifespan\<6 months 11. Researchers believe that participants are not suitable to participate in this trial (such as pregnancy, severe visual or hearing impairment, etc.) 12. Individuals who are unable to understand and/or comply with this research procedure (such as those who are addicted to alcohol, substance abuse, or have mental illnesses) 13. Currently participating in clinical trials of other devices or drugs 14. Researchers involved in the design and execution of this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.